Having the first point of care, autologous skincare product for home use has been exciting for the company, and we are thrilled that our scientific findings are contributing to the new field of knowledge for regenerative aesthetic medicine”, says MaryAnn Guerra, ABM’s, President/CEO.
PHOENIX (PRWEB) December 16, 2019
Aesthetics Biomedical, a company committed to the development and distribution of innovative aesthetic devices, products, and services for the global market, announce scientific findings for its proprietary SoME™ Skincare product. SoME™ is the first of its kind topical product that provides the vehicle for a personalized autologous platelet rich plasma (PRP) skincare product for home use. The field of personalized aesthetics and the use of PRP to effectively achieve aesthetic outcomes is expanding daily, providing new opportunities to advance the science. Contributing to this knowledge base, the results from ABM’s controlled, blinded, eight-week study was recently published in the (J Cosmetic Dermatology Vol 18,Issue 5, 2019; Dermatology Times Vol 40, Issue 9,2019 ). The data indicated that the proprietary SoME™ cosmetic base, when combined with autologous PRP, could demonstrate identifiable clinical improvement for signs of facial aging at four weeks, with enhanced performance observed at eight weeks (e.g., luminosity, radiance, smoothness, reduction in redness and skin lightening) vs the control base alone. Biopsies revealed enhanced collagen and elastin expression, with the SoME™ + PRP vs the SoME™ alone.
The proprietary cosmetic base is to keep the SoME™ + PRP stable for 90 days. As a point of care product, the patient visits their physician office, has blood drawn that is centrifuged to obtain PRP. The PRP is then added to three 1oz bottles of the SoME™ cosmetic base providing for three months, twice a day home use. The patient receives a mini-cosmetic refrigerator to conveniently store the product. An additional 120-day study is underway to further verify the clinical, histological, biochemical findings, and to validate that continued use leads to further enhanced cosmetic improvement. The product is well tolerated by all skin types; the preservative system has antimicrobial and antibacterial properties (a full cosmetic preservative package). Other aesthetic treatments can be performed and used concurrently with SoME™.
“We entered into this PRP treatment arena, realizing that there was a paucity of controlled studies generating important data involving PRP, not only for topical use but for aesthetic use in general. ABM is very focused on conducting critical science that supports both our topical products and aesthetic devices. Having the first point of care, autologous skincare product for home use has been exciting for the company, and we are thrilled that our scientific findings are contributing to the new field of knowledge for regenerative aesthetic medicine”, says MaryAnn Guerra, ABM’s, President/CEO.
Lawrence Rheins Ph.D., Chief Scientific Officer and one of the authors on the publication, stated, “our ongoing studies continually provide critical evidence on the growing role of the platelet in aesthetic medicine and other skin indications. An additional focus for 2020 will be to evaluate the role of SoME™ as a simplified anti-aging treatment approach to reduce the current practice of using multiple skincare product regimens and the value of using the body’s own platelet-rich biomolecules, as the key source to provide a comprehensive regenerative aesthetic appearance.”
About Aesthetics Biomedical: Aesthetics Biomedical is committed to the development and distribution of innovative aesthetic devices, products, and services for the global market. ABM creates novel patient treatment experiences that ensure our products yield desired results, keeping patient comfort in mind. Aesthetics Biomedical's SoME™ products are intended to meet the FDA's definition of a cosmetic; an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. ABM products do not contain platelet rich plasma and are not intended to be drug or biologic products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA, and the statements on these products have not been evaluated by the FDA.